Paolo Tarantino: Impressive activity with tucatinib plus trastuzumab for HER2-mutated breast cancer
Paolo Tarantino shared on X:
“Impressive activity with tucatinib plus trastuzumab for HER2-mutated breast cancer. .
Among 31 patients with HER2-mutation MBC (mostly with HR+ and lobular disease), ORR with tucatinib/trastuzumab (plus fulvestrant, if HR positive) was 42%, with mDoR of 12.6 months and mPFS of 9.5 months.”
Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer.
Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.